Prolongation of Levodopa Responses by GlycineB Antagonists in Parkinsonian Primates

• Type of Material: Article
• Authors: Stella M. Papa, Emory University; Yves P. Auberson, Novartis Institutes for Biomedical Research; J. Timothy Greenamyre, Emory University
• Language: English
• Date: 2004-11
• Publisher: Wiley: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2004 American Neurological Association
• Final Published Version (URL): http://onlinelibrary.wiley.com/doi/10.1002/ana.20279/abstract
• Title of Journal or Parent Work: Annals of Neurology
• ISSN: 0364-5134
• Volume: 56
• Issue: 5
• Start Page: 723
• End Page: 727
• Research Categories: Biology, Neuroscience

Abstract

To examine the antiparkinsonian effects of blocking glycineB receptors, we designed a pilot study testing the potent and selective antagonist, PAMQX, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. PAMQX had no intrinsic effects but markedly potentiated the antiparkinsonian action of levodopa. In a dose-dependent fashion, coadministration of the glycineB antagonist with levodopa extended the response duration by nearly 60%. It is noteworthy that PAMQX, within a considerable dose range, did not cause ataxia or other side effects. These data indicate that blocking N-methyl-d-aspartate receptors selectively to manipulate dopaminergic-mediated motor responses may be produced effectively by glycineB antagonists.